Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$3.50 - $22.22
Previous CloseN/A
Volume25.00K
Average Volume (3M)53.85K
Market Cap
$12.05M
Enterprise Value$11.99M
Total Cash (Recent Filing)$5.39M
Total Debt (Recent Filing)$4.73M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 12, 2026EPS Estimate
-1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.43
Shares Outstanding3,019,534
10 Day Avg. Volume29,931
30 Day Avg. Volume53,850
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.05
Enterprise Value/Gross Profit9.50
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$30.00Price Target Upside4009.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.53
Revenue Forecast (FY)$3.77M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue growth across multiple years shows the company is gaining commercial traction with clinicians and expanding product adoption. This durable top-line improvement supports scaling opportunities, incremental operating leverage potential, and validates the market need for its women’s health diagnostics and related consumables.
Healthy Gross Margins And Manufacturing ScaleSustained mid-to-high gross margins indicate the product economics can support profitable unit sales as volumes rise. Combined with claims of scalable U.S. manufacturing and regulatory approvals, this underpins a durable ability to convert revenue growth into improved gross profit and to serve larger clinical markets over the medium term.
Improved Leverage And Listing/Governance StabilityMeaningfully lower leverage and increased equity provide a stronger capital cushion versus prior periods. Regaining Nasdaq compliance and refreshing governance/audit oversight reduces delisting risk and supports continuity, improving the firm's structural ability to execute commercial plans and access capital when needed.
Bears Say
High And Persistent Cash BurnLarge, sustained negative operating and free cash flow indicate the business is not yet self-funding and requires ongoing external capital. Over months this pressure constrains strategic flexibility, risks delaying commercialization investments, and forces management to prioritize financing over long-term R&D or go-to-market programs.
Very Large Operating And Net LossesExtremely negative operating and net margins show the cost base far exceeds current revenue and that scaling has not yet delivered profitability. Persistent heavy losses depress returns and indicate structural cost or scale challenges that must be resolved for durable shareholder value creation.
Dependence On External Financing / Dilution RiskAuthorization to issue sizeable equity on conversion/exercise highlights reliance on outside capital to fund operations. This creates dilution risk for existing holders and signals that without a near-term path to sustained positive cash flow, future financings may be required, constraining long-term capitalization stability.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $3.50 and its highest was $22.22 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $12.05M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 29 days.
How were Femasys, Inc.’s earnings last quarter?
Currently, no data Available
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate is -1.27.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 3,019,534 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
FEMY Stock 12 Month Forecast
Average Price Target
$30.00
▲(4009.59% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
2.83% Insiders
2.62% Mutual Funds
11.06% Other Institutional Investors
81.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---